[billorites]

Stockholders will have a fit.

[Fractal Trader]

This is just sour grapes from the regulatory world. This article is nothing new.

Any practitioner will tell you that Neurontin is a highly effective drug for many off-label purposes. However, since the drug is near patent expiration and the costs of trials are extremely high, it is assuredly unprofitable to try to prove its efficacy in traditional manners.

Many drugs have been marketed off label with no complaints. I think what the attorneys general would really like is some money to line their products, not drug reform.

[dawn53]

I've got no problem with Neurontin being used for other purposes. I do have a problem if indeed doctors are receiving "paid kickbacks" for prescribing certain drugs.